The GLP-1 analogue liraglutide can improve blood glucose control when given once a day, a study has shown.The drug is currently in development and is expected to be launched later this year.
In the latest study, nearly 500 patients with inadequately controlled type-2 diabetes, who were taking metformin with or without a sulfonylurea, were given liraglutide or the twice- daily GLP-1 analogue exenatide and monitored for change in HbA1c.
Liraglutide reduced the mean HbA1c by 1.12 per cent compared with a reduction of 0.79 per cent for patients on exenatide.
More patients achieved an HbA1c level of less than 7 per cent in the liraglutide group than in the exenatide group.
Professor Stephen Gough, professor of medicine and honorary consultant physician at the University of Birmingham said he thought the drug would be suitable for use after metformin for most type-2 diabetes patients.
The findings were presented at the American Diabetes Association meeting in New Orleans this week.
Comment below and tell us what you think